Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for ...

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Eli Lilly & Co on Monday unveiled a new multi-dose form of its blockbuster obesity drug Zepbound, allowing patients to ...

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

Lilly launches four-dose Zepbound KwikPen in the US. Self-pay starter price begins at $299 per month. Move aims to improve retention in crowded GLP-1 market. Millions of people on GLP-1 weight-loss ...

Eli Lilly has rolled out a multi-dose KwikPen version of tirzepatide, marketed as Zepbound, for chronic weight management—signaling a packaging update for one of the obesity market’s fastest-expanding ...

Consolidation of four doses may lower secondary packaging complexity and improve fill-finish throughput predictability, although Lilly has not quantified manufacturing efficiency gains. Multi-dose use ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...